By: Darcy Lewis From: onclive.com In breast cancer, neoadjuvant endocrine therapy shows promise in a variety of areas, including as an excellent testing platform, Ingrid A. Mayer, MD, MSCI, said in a presentation during the 2019 Lynn Sage Breast Cancer Symposium.1 Neoadjuvant endocrine therapy allows clinicians to determine resistance mechanisms to endocrine therapy with or without targeted agents. It also …
Cognitive-Behavioral Therapy Reduces Endocrine Treatment Side Effects in Breast Cancer Patients
By: Lidia Schapira, MD From: medscape.com Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial Study Summary Adjuvant endocrine therapy for breast cancer, through treatment-induced profound estrogen deprivation, leads to hot flashes (HF) and night sweats (NS). These symptoms affect women’s daily functioning and health-related quality of life and, …
CTC Counts Hold Value in Therapy Selection for Metastatic Breast Cancer
By: Tony Hagen From: targetedonc.com At the 2018 San Antonio Breast Cancer Symposium, data demonstrated that use of circulating tumor-cell (CTC) counts had strong value for selecting endocrine therapy compared to chemotherapy in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. A CTC cutoff value was used to determine first-line treatment in this double-arm, randomized trial. There was high concordance between clinician’s choice …
Long Haul for Breast Cancer Survivors: Disease Can Return After 20 Years
From: healthline.com New research shows that long-term endocrine therapy can reduce the risk of breast cancer recurrence in the long term. But side effects keep some women from taking it. Like many breast cancer survivors, Julie Barthels wonders if the disease will return. “My breast cancer came silently, without my knowledge. How do I know what is silently growing inside …
Hormonal therapy for breast cancer can also increase risk of developing chronic conditions
By: Elisa Black From: news.com.au WOMEN who receive hormonal therapy for breast cancer are at increased risk of developing chronic conditions later in life. New research by Flinders University and the University of South Australia, published in the Medical Journal of Australia yesterday, found that rates of depression, osteoporosis, diabetes, cardiovascular conditions, chronic pain and gastric disorders were higher among …
ASCO: Studies Demonstrate Predictive Power of bioTheranostics’ Breast Cancer Index Molecular Test in Treatment Decisions
Ability to Predict Benefit from Extended Endocrine Therapy Impacts Treatment & Reduces Patient Anxiety bioTheranostics, Inc., today announced results from studies being presented at the 2015 American Society of Clinical Oncology (ASCO) meeting reinforcing the role its Breast Cancer Index (BCI) molecular test plays in informing decisions about extending endocrine therapy beyond five years post-diagnosis for patients with early stage, estrogen receptor-positive …